Obstructive sleep apnoea and metabolic syndrome: Put CPAP efficacy in a more realistic perspective

Thorax

Volumn 67, Issue 12, 2012, Pages 1025-1027

  Pépin, Jean Louis ^a,b   Tamisier, Renaud ^a,b   Lévy, Patrick ^a,b  

^a UNIV GRENOBLE ALPES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CHOLESTEROL; CHYLOMICRON; FATTY ACID; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INTERLEUKIN 6; LIPOPROTEIN LIPASE; PHOSPHOLIPID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTIFICIAL VENTILATION; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DEATH; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHRONIC INTERMITTENT HYPOXIA; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; EDITORIAL; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE UTILIZATION; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID METABOLISM; METABOLIC SYNDROME X; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHOSPHOLIPID SYNTHESIS; PHYSICAL ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RISK REDUCTION; SLEEP DISORDERED BREATHING; SUBCUTANEOUS FAT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84869237090     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202807     Document Type: Editorial

References (24)

1. The L. Time for action in New York on non-communicable diseases. Lancet 2011;378:961.
2. Levy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009;34:243-60.
3. Morselli LL, Guyon A, Spiegel K. Sleep and metabolic function. Pflugers Arch 2012;463:139-60.
4. Tamisier R, Pepin JL, Remy J, et al. 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Eur Respir J 2011;37:119-28.
5. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007;175:851-7. (Pubitemid 46631798)
6. Xu J, Long Y-S, Gozal D, et al. β-cell death and proliferation after intermittent hypoxia: Role of oxidative stress. Free Radic Biol Med 2009;46:783-90.
7. Aron-Wisnewsky J, Minville C, Tordjman J, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012;56:225-33.
8. Drager L, Polotsky V. Lipid Metabolism: A New Frontier in Sleep Apnea Research. Am J Respir Crit Care Med 2011;184:288-90.
9. Drager LF, Li J, Reinke C, et al. Intermittent Hypoxia Exacerbates Metabolic Effects of Diet-Induced Obesity. Obesity 2011;19:2167-74.
10. Reinke C, Bevans-Fonti S, Drager LF, et al. Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J Appl Physiol 2011;111:881-90.
11. Sharma SK, Agrawal S, Damodaran D, et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med 2011;365:2277-86.
12. Hoyos CM, Killick R, Yee BJ, et al. Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study. Thorax. Published Online First: 5 May 2012. doi:10.1136/thoraxjnl-2011-201420.
13. West SD, Nicoll DJ, Wallace TM, et al. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007;62:969-74. (Pubitemid 350084496)
14. Coughlin SR, Mawdsley L, Mugarza JA, et al. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007;29:720-7. (Pubitemid 46554622)
15. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004;169:156-62. (Pubitemid 38114528)
16. Hecht L, Mohler R, Meyer G. Effects of CPAP-respiration on markers of glucose metabolism in patients with obstructive sleep apnoea syndrome: a systematic review and meta-analysis. Ger Med Sci 2011;9:Doc20.
17. Phillips CL, Yee BJ, Marshall NS, et al. Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea. Am J Respir Crit Care Med 2011;184:355-61.
18. Sivam S, Phillips CL, Trenell MI, et al. Effects of 8 weeks of continuous positive airway pressure on abdominal adiposity in obstructive sleep apnoea. Eur Respir J 2012;40:913-18.
19. West SD, Kohler M, Nicoll DJ, et al. The effect of continuous positive airway pressure treatment on physical activity in patients with obstructive sleep apnoea: A randomised controlled trial. Sleep Med 2009;10:1056-8.
20. Weinstock TG, Wang X, Rueschman M, et al. A controlled trial of CPAP therapy on metabolic control in individuals with impaired glucose tolerance and sleep apnea. Sleep 2012;35:617-25B.
21. Craig S, Kohler M, Nicoll DJ, et al. Continuous Positive Airway Pressure (CPAP) improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea (OSA); the MOSAIC randomised controlled trial. Thorax Published Online First: 30 Oct 2012. doi:10.1136/thoraxjnl-2012-202178
22. Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 2007;167:757-64.
23. Lam JC, Mak JC, Ip MS. Obesity, obstructive sleep apnoea and metabolic syndrome. Respirology 2012;17:223-36.
24. Borel AL, Leblanc X, Almeras N, et al. Sleep apnoea attenuates the effects of a lifestyle intervention programme in men with visceral obesity. Thorax 2012;67:735-41.